21-Aug-2026
TipRanks (Tue, 18-Aug 10:40 AM ET)
TipRanks (Tue, 18-Aug 6:35 AM ET)
TipRanks (Tue, 18-Aug 5:30 AM ET)
Globe Newswire (Tue, 11-Aug 4:05 PM ET)
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
Globe Newswire (Mon, 10-Aug 4:05 PM ET)
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
Globe Newswire (Thu, 23-Jul 8:00 AM ET)
Globe Newswire (Thu, 16-Jul 3:22 PM ET)
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
Globe Newswire (Mon, 29-Jun 8:00 AM ET)
Globe Newswire (Mon, 22-Jun 2:07 PM ET)
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Insight Molecular Diagnostics trades on the NASDAQ stock market under the symbol IMDX.
As of August 21, 2026, IMDX stock price climbed to $4.34 with 37,749 million shares trading.
IMDX has a beta of 2.88, meaning it tends to be more sensitive to market movements. IMDX has a correlation of 0.15 to the broad based SPY ETF.
IMDX has a market cap of $142.02 million. This is considered a Micro Cap stock.
Last quarter Insight Molecular Diagnostics reported $239,000 in Revenue and -$.23 earnings per share. This fell short of revenue expectation by $-198,500 and met earnings estimates .
The top ETF exchange traded funds that IMDX belongs to (by Net Assets): VTI, VXF, IWC.
IMDX has outperformed the market in the last year with a return of +75.0%, while the SPY ETF gained +21.7%. However, in the most recent history, IMDX shares have underperformed the stock market with its stock returning -26.2% in the last 3 month period and -10.1% for the last 2 week period, while SPY has returned +3.4% and -1.0%, respectively.
IMDX support price is $4.01 and resistance is $4.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMDX shares will trade within this expected range on the day.